Modelling the potential clinical and economic impact of universal antenatal hepatitis C (HCV) screening and providing treatment for pregnant women with HCV and their infants in Egy... by Giuseppe Indolfi, Diana M Gibb, Aya Mostafa, Sarah Pett, Yazdan Yazdanpanah, Sylvie Deuffic-Burban, Anthony E Ades, Karen Scott, Ali Judd, Nadia Hachicha-Maalej, Clotilde Lepers, Intira Jeannie Collins, Manal H El Sayed

“…Backgrounds and aims Pregnant women and children are not included in Egypt’s hepatitis C virus (HCV) elimination programmes. This study assesses the cost-effectiveness of several screening and treatment strategies for pregnant women and infants in Egypt.Design A Markov model was developed to simulate the cascade of care and HCV disease progression among pregnant women and their infants according to different screening and treatment strategies, which included: targeted versus universal antenatal screening; treatment of women in pregnancy or deferred till after breast feeding; treatment of infected children at 3 years vs 12 years. …”
Get full text

Single or multiple treatments with lusutrombopag in subjects with thrombocytopenia and chronic liver disease needing an invasive procedure by Davide Scalabrini, Paolo Sciuto, Cristina Felicani, Antonia Rudilosso, Pietro Andreone

“…This article reports two different cases concerning respectively an 83-year-old female patient suffering from arterial hypertension, aneurysm of the sub-renal aorta, hepatitis C virus (HCV)-positive liver cirrhosis responsive to treatment with antiviral drugs, and a 2.0 cm diameter hepatocellular carcinoma (HCC) nodule localized in the hepatic segment III and a 53-year-old female patient with HCV-positive liver cirrhosis complicated by portal hypertension with splenomegaly, thrombocytopenia, and F3 esophageal varices at high risk of bleeding. …”
Get full text

Prospective evaluation of the impact of repeated whole prison testing for hepatitis C by Stuart McPherson, Naw April Phaw, Manoj Valappil, Carolyn Miller, Craig Thompson, Francesca McCullough, Caroline Allsop, Kate McQue, Ryan Jelley, Jenna Kerry, Jodi Aldridge, Tony Jefferson, Colin Lawton, Lee Christensen, Aung Min Thant

“…Introduction Chronic hepatitis C virus (HCV) infection is prevalent in prisons. …”
Get full text

Donor Small-Droplet Macrovesicular Steatosis Affects Liver Transplant Outcome in HCV-Negative Recipients by Flaminia Ferri, Quirino Lai, Antonio Molinaro, Edoardo Poli, Lucia Parlati, Barbara Lattanzi, Gianluca Mennini, Fabio Melandro, Francesco Pugliese, Federica Maldarelli, Alessandro Corsi, Mara Riminucci, Manuela Merli, Massimo Rossi, Stefano Ginanni Corradini

“…No data are available on liver transplantation (LT) outcome and donor liver steatosis, classified as large droplet macrovesicular (Ld-MaS), small-droplet macrovesicular (Sd-MaS), and true microvesicular (MiS), taking into account the recipient Hepatitis C virus (HCV) status. Aim. We investigate the impact of allograft steatosis reclassified according to the Brunt classification on early graft function and survival after LT. …”
Get full text

Interplay of PNPLA3 and HSD17B13 Variants in Modulating the Risk of Hepatocellular Carcinoma among Hepatitis C Patients by Carla De Benedittis, Mattia Bellan, Martina Crevola, Elena Boin, Matteo Nazzareno Barbaglia, Venkata Ramana Mallela, Paolo Ravanini, Elisa Ceriani, Stefano Fangazio, Pier Paolo Sainaghi, Michela Emma Burlone, Rosalba Minisini, Mario Pirisi

“…Our aim was to evaluate if the same holds true in chronic hepatitis C virus infection (HCV). With a case control retrospective study design, we selected 110 patients who developed HCC on a background of HCV infection, matching each patient for sex and age (±30 months) to three HCV-infected, non-HCC patients. …”
Get full text

Feasibility and Acceptability of Antenatal Hepatitis C Screening: A Pilot Study by Joseph Valamparampil, Jaswant Sira, Maxine Brown, Saket Singhal, Deirdre Kelly

“…Introduction. Hepatitis C virus (HCV) is not currently included in the United Kingdom routine antenatal screening program, but the latest guidelines from the Centers for Disease Control and Prevention, American Association for the Study of Liver Diseases, and Infectious Diseases Society of America recommend HCV screening for all pregnant women during each pregnancy. …”
Get full text

Treatment of chronic hepatitis C by cepeginterferon alpha-2b in combination to ribavirin by M. V. Mayevskaya, O. O. Znoyko, Ye. A. Klimova, S. L. Maximov, S. N. Kizhlo, N. A. Petrochenkova, F. I. Nagimova, Yu. N. Linkova

“…Study results prove high efficacy and safety of Algeron in suppression of hepatitis C virus replication and allow to recommend its application at previously untreated patients with CHC in a doze of 1,5 mkg/kg/wk for 24-48 wks in relation to genotype HCV.…”
Get full text

Structure of Patients with Hepatocellular Cancer (Data Analysis from Two Specialised Centres) by M. V. Mayevskaya, M. S. Novruzbekov, I. M. Borovkov, D. G. Trofimova, M. S. Zharkova, V. D. Lunkov, K. N. Lutsyk, O. D. Olisov

“…An increase in the number of patients with autoimmune LC and LC associated with chronic hepatitis C virus (HCV) infection was observed. The conducted analysis of trends in the structure of HCC patients showed that chronic HCV and HBV infection is the main prerequisite for the development of cancer. …”
Get full text

Hepatitis B and C Viruses’ Infection and Associated Factors among Pregnant Women Attending Antenatal Care in Hospitals in the Amhara National Regional State, Ethiopia by Mulat Dagnew, Yihenew Million, Mucheye Gizachew, Setegn Eshetie, Gashaw Yitayew, Lakachew Asrade, Mulat Adefris, Feleke Moges, Moges Tiruneh

“…Serum samples were tested for hepatitis B surface antigen (HBsAg) and anti-hepatitis C virus antibody (anti-HCV) using ELISA. SPSS version 20 was used for data analysis, and a multivariable logistic regression analysis was used to assess the relationship between factors associated with hepatitis B virus and hepatitis virus C infection. …”
Get full text

Liver damage in patients living with HIV on antiretroviral treatment with normal baseline liver function and without HBV/HCV infection: an 11-year retrospective cohort study in Gua... by Jun Yu, Hao Liang, Fengxiang Qin, Junjun Jiang, Chunwei Qin, Yunxuan Huang, Bingyu Liang, Yuexiang Xu, Jiegang Huang, Zhiliang Xu, Chuanyi Ning, Yanyan Liao, Ning Zang, Jingzhen Lai, Wudi Wei, Li Ye, Xionglin Qin

“…Objective To characterise the association between duration of exposure to antiretroviral treatment (ART) and liver damage in HIV patients with an initially normal baseline liver function and without hepatitis B virus (HBV)/hepatitis C virus (HCV) infection.Methods A retrospective cohort study was conducted in HIV-infected individuals with normal liver function parameters at ART initiation and without HBV/HCV infection, from 14 April 2004 to 13 April 2015 in Guigang city, Guangxi, China. …”
Get full text

Glucose Metabolism Changes in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals by Sylvia Drazilova, Martin Janicko, Lubomir Skladany, Pavol Kristian, Marian Oltman, Maria Szantova, Dusan Krkoska, Eva Mazuchova, Lubica Piesecka, Veronika Vahalova, Marek Rac, Ivan Schreter, Ladislav Virag, Tomas Koller, Adriana Liptakova, Miriam Ondrasova, Peter Jarcuska

“…Data about glycemia, history of diabetes, hepatitis C virus, treatment, and liver status, including elastography, were obtained at baseline (before treatment start), at the end of treatment and 12 weeks after the end of treatment. …”
Get full text

Real-life study on the effectiveness and safety of sofosbuvir/velpatasvir-based antiviral agents for hepatitis C eradication in Chinese patients by Jiayi Wang, Lingyao Du, Dongmei Zhang, Chen Zhou, Yilan Zeng, Miao Liu, Xing Cheng, Xiaona Song, Han Chen, Ning Han, Enqiang Chen, Hong Tang

“…Background: Hepatitis C virus (HCV) eradication with sofosbuvir/velpatasvir (SOF/VEL) represents a significant advancement, offering hope for eliminating the virus in diverse patient populations. …”
Get full text

Pegilated interferon alpha 2b «Pegaltevir» chronic hepatitis C treatment (randomized clinical trial) by Marina V. Mayevskaya, Ye. N. Bessonova, P. O. Bogomolov, N. I. Geyvandova, K. V. Zhdanov, V. G. Morozov, V. D. Pasechnikov, I. Yu. Khomenko, A. V. Yagoda, V. T. Ivashkin

“…Beneficial interferon properties include: absence of mutagenic capacity for hepatitis C virus and drug interaction, stimulation of host immune response. …”
Get full text

Protein tyrosine phosphatase delta is a STAT3-phosphatase and suppressor of metabolic liver disease by Thomas F Baumert, Charlotte Bach, Patrick Pessaux, Catherine Schuster, Frank Jühling, Sarah C Durand, Yujin Hoshida, Fabien Zoulim, Atish Mukherji, Naoto Fujiwara, Marine A Oudot, Armando Andres Roca Suarez, Michel L Tremblay, Barbara Testoni, Joachim Lupberger, Romain Parent, Laurent Mailly, Nassim Dali-Youcef, Emanuele Felli, Maria Saez-Palma, Julien Moehlin, Alessia Virzì, Nicolas Brignon, Eugenie Schaeffer, Romain Martin, Laura Meiss-Heydmann, Zakaria Boulahtouf, Lea Girard, Emma Osswald, Carole Jamey, Daniel Brumaru, Bhuvaneswari Koneru

“…Objective Impaired hepatic expression of protein tyrosine phosphatase delta (PTPRD) is associated with increased STAT3 transcriptional activity and reduced survival from hepatocellular carcinoma in patients with chronic hepatitis C virus infection. However, the PTPRD-expressing hepatic cell types, signalling pathways responsive to PTPRD and their role in non-viral liver disease are largely unknown.Methods We studied PTPRD expression in single-cell and bulk liver transcriptomic data from mice and humans, and established a Ptprd-deficient mouse model for metabolic dysfunction-associated steatohepatitis (MASH). …”
Get full text

Organizing Pneumonia Associated with Pegylated Interferon α and Ribavirin Therapy by Amit Chopra, Creticus Marak, Narendrakumar Alappan, Chang Shim

“…Hepatitis C virus infection is the leading cause of chronic liver disease in the United States of America. …”
Get full text

An Unexpected Interaction between Sofosbuvir/Ledipasvir and Atorvastatin and Colchicine Causing Rhabdomyolysis in a Patient with Impaired Renal Function by Shyam Patel, Jennifer Andres, Kamran Qureshi

“…Hepatitis C virus (HCV) infection affects roughly 170 million people worldwide. …”
Get full text

Risk-Based Prenatal Hepatitis C Testing Practices and Results, Alaska 2013-2016 by Leisha D. Nolen, Courtney Gustin, Sara Seeman, Neil Murphy, Sarah Truitt, Sarah Schillie, Michael G. Bruce, Dana Bruden, James Tiesinga, Brian McMahon

“…Hepatitis C virus (HCV) infection in pregnant women is of concern as it presents a health threat not only to the mother, but also to her infant. …”
Get full text

Differentiated approach at the choice of chronic hepatitis C antiviral therapy mode (real clinical practice experience) by I. Yu. Pirogova, N. B. Kovaleva, E. P. Patlusov, E. S. Radchenko

“…Overall 164 patients with hepatitis C viruses (HCV) genotypes 1, 2 and 3 in 4 medical centers received antiviral therapy. …”
Get full text